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Prevalence of asthma–COPD overlap syndrome among
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a cross-sectional study
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BACKGROUND: The overlap between asthma and chronic obstructive pulmonary disease (COPD) is an important clinical
phenomenon. However, the prevalence of asthma–COPD overlap syndrome (ACOS) is not known.
AIMS: To investigate the prevalence of ACOS among asthmatic patients with a smoking history, and evaluate the factors predicting
ACOS in this patient group.
METHODS: We investigated 190 primary care asthma patients with no previous diagnosis of COPD, but who were either current or
ex-smokers, with a smoking history of at least 10 pack-years. Spirometry was performed on all the patients while they were taking
their normal asthma medication. Patients were considered to have ACOS if their postbronchodilator forced expiratory volume in
1 s/forced vital capacity was o0.70.
RESULTS: Fifty-two (27.4%) of the patients were found to have ACOS. Age ⩾ 60 years and smoking for ⩾ 20 pack-years were the
best predictors of ACOS. If both of these criteria were met, the odds ratio (95% conﬁdence interval) for ACOS was 6.08 (2.11–17.49),
compared with the situation where neither of these criteria were fulﬁlled.
CONCLUSIONS: There is a high prevalence of ACOS among primary health care asthmatics with a positive smoking history but no
previous diagnosis of COPD. In this population, age over 60 years and a smoking history of more than 20 pack-years were the best
predictors of ACOS.
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INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are
the two most common obstructive pulmonary diseases. Although
asthma and COPD most often represent two distinct diseases,
there is also signiﬁcant overlap between these two diseases.1,2
The deﬁnition of asthma–COPD overlap syndrome (ACOS) is
undetermined. Most commonly, it is deﬁned as either the
diagnosis of COPD in a patient with previously diagnosed asthma,
or as incompletely reversible airway obstruction accompanied by
symptoms or signals of increased reversibility of the obstruction.3
A recent update of the GINA report recommended a stepwise
approach to the diagnosis of ACOS, and deﬁned it as a syndrome
characterized by persistent airﬂow limitation with several features
usually associated with asthma and several features usually
associated with COPD.1
Compared with asthma or COPD alone, ACOS is associated
with worse health-related quality of life,4,5 more frequent
exacerbations,5,6 increased hospitalisation6,7 and higher health
care costs.8 Although ACOS appears to be clinically highly
signiﬁcant, little is known about the treatment of these patients,
as they are typically excluded from therapy trials for asthma
or COPD.9
There is only some data on the prevalence of ACOS. Hardin
et al.5 found that 13% of the COPD patients in the COPDGene
study reported a history of doctor-diagnosed asthma. Similarly,
Miravitlles et al.10 reported that 17.4% of COPD patients in the
EPI-SCAN study reported that they had been previously diagnosed
with asthma. The prevalence of overlap syndrome has been
shown to increase with age,11 which may reﬂect the fact that, over
the years, asthmatics may develop ﬁxed airway obstruction,
especially if they do not use anti-inﬂammatory medication12 or if
they smoke.13 Soriano et al.11 found that as many as half of the
patients with obstructive pulmonary disease, aged 50 years or
more, had simultaneously more than one obstructive condition.
The aim of the present study was to investigate the prevalence
of undiagnosed ACOS among primary health care asthma patients
who are current or ex-smokers, and the factors predicting ACOS in
this patient group.
MATERIALS AND METHODS
This was a cross-sectional study. Patients were recruited mostly from the
appointments of primary care physicians and through newspaper
advertisements. In addition, a few patients were also recruited by private
pulmonologists treating primary care-like asthma patients.
The study was approved by the Ethics Committee of Pirkanmaa Health
Care District, and every patient gave written informed consent before any
study-related procedures were performed.
Patients
The inclusion criteria were as follows: age 18–70 years, current or
ex-smoker with 10 or more pack-years, doctor-diagnosed asthma with
special reimbursement for asthma medication granted by the National
Health Insurance. To qualify for this reimbursement, patients must have
fulﬁlled at least one of the following criteria: (1)⩾ 12% (and 200ml)
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reversibility in forced expiratory volume in 1 s (FEV1) or forced vital capacity
(FVC) in a bronchodilation test, (2) during a 2-week peak expiratory ﬂow
monitoring at least three times either a bronchodilator response of ⩾ 15%
(and 60 l/min) or a diurnal variation of ⩾ 20%, (3) moderate-to-severe
bronchial hyperresponsiveness in histamine or methacholine inhalation
challenge or (4) FEV1 had improved more than 15% during a corticosteroid
treatment test.
The exclusion criteria were as follows: any severe illness, any known
pulmonary disease other than asthma, use of inhaled anticholinergic or
indacaterol or oral roﬂumilast.
Methods
After informed consent was received, the investigator and the patient
completed a questionnaire including questions about the inclusion and
exclusion criteria, and the patient’s asthma medication, symptoms and
exacerbations. The investigator stored the data in a database. Body mass
index and current smoking status were recorded as a standard procedure
when spirometry was performed.
Spirometries (Medikro Kuopio, Finland) were performed according to
the guidelines14 before and after administration of 400 μg of inhaled
salbutamol while the patients were taking their usual asthma medication.
The patients were considered to have ACOS if their postbronchodilator
FEV1/FVC was less than 0.70. Patients with ACOS were divided into GOLD
grades of airway obstruction according to the GOLD report.2
Patients were considered to have had an exacerbation during the
previous year if they had been hospitalised, or had used a course of oral
corticosteroids, for their asthma during the previous year.
Statistical analysis
The primary outcome was the prevalence of ACOS, as deﬁned above,
among asthmatics with a smoking history of at least 10 pack-years. The
sample size calculation was based on the assumption that the prevalence
of ACOS in asthmatics is approximately 45%.11 Using the large sample
normal approximation, 265, 195, 149, 118 or 96 patients would be required
to estimate the prevalence to be 95% conﬁdent that the estimate will not
differ from the true prevalence by more than 6, 7, 8, 9 or 10 percent,
respectively. The ﬁnal sample size of 219 recruited patients was assessed to
be large enough to obtain a sufﬁcient precision. The 95% conﬁdence
interval for prevalence was calculated using the large sample normal
approximation. The distribution of the variables was checked using the
Kolmogorov–Smirnov test and graphical plots. The distributions of
demographic continuous data were skewed and are expressed as medians
(interquartile range). The nonparametric Mann–Whitney U-test was used to
compare the groups with and without ACOS with respect to continuous
variables. The Chi-square test and the exact Fisher's test, when appropriate,
were used for categorical variables. Spearman’s rank correlation (Rho) was
used to study the associations between postbronchodilator FEV1/FVC
versus age and pack-years. The receiver operating curve analysis (ROC)
was used to determine the best cut-off values of age and pack-years
to differentiate between asthma patients with and without overlap
syndrome. Sensitivity and speciﬁcity were assessed to be equally important
when the best cut-off values were chosen. In addition, positive predictive
values and negative predictive values were calculated. The potential
prognostic factors for overlap were sex, age, body mass index, current
smoking status and pack-years of smoking. Univariable logistic regression
analyses were performed to study the associations. The results are given as
odds ratios with 95% conﬁdence intervals. P values less than 0.05 were
considered statistically signiﬁcant. The analyses were performed using IBM
SPSS Statistics for Windows (version 22.0, Armonk, NY, USA, IBM Corp.).
RESULTS
Two hundred and nineteen patients were recruited and 190 of
them were included in the analysis (Figure 1). Their median age
(range) was 58 (23–70) years, they had smoked for 20 (10–60)
pack-years, and their body mass index was 27.5 (16.1–50.3) kg/m2.
Eighty-three (44.1%) of the patients were current smokers and 112
(58.9%) were female.
Fifty-two (27.4%, 95% conﬁdence interval 21–34%) patients
were found to have postbronchodilator FEV1/FVC o0.70 and
were thus considered to have ACOS. Twelve (23.1%), 38 (73.1%)
Asthma patients,
n = 219
Spirometry measurements
were not available,
n = 26
Spirometry measurements
were available,
n = 193
Spirometry was not valid,
n = 3 
Patients included
in analysis,
n = 190 
Postbronchodilator
FEV1/FVC < 0.70,
n = 52 (27.4%)
Postbronchodilator
FEV1/FVC > 0.70,
n = 138 (72.6%)
Figure 1. Flow of participants. FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity.
Table 1. Characteristics of 190 asthmatics with and without overlap syndrome
Patients with overlap syndrome
(N= 52)
Patients with asthma only
(N= 138)
P valuea
Age (years) 63.0 (52.5–66.5) 57.0 (49.0–64.0) 0.008
Pack-years 24.5 (20.0–37.0) 20.0 (13.0–28.0) 0.003
BMI (kg/m2) 26.2 (23.2–29.9) 27.8 (24.6–31.6) 0.09
Current smokers 28 (54.9%) 55 (40.1%) 0.07
Females 31 (59.6%) 81 (58.7%) 0.91
Inhaled corticosteroid (ICS) 50 (96.2%) 129 (93.5%) 0.48
Inhaled corticosteroid+inhaled long-acting β2-agonist (ICS+LABA) 36 (69.2%) 86 (62.3%) 0.38
Short-acting β-agonist (SABA) more often than twice a week 19 (36.5%) 37 (26.8%) 0.19
Exacerbation during previous year 16 (30.8%) 35 (25.4%) 0.45
Signiﬁcant reversibility 8 (15.4%) 9 (6.5%) 0.08b
All patients were current or ex-smokers. Results are given as median (interquartile range) or number (%).
Abbreviation: BMI, body mass index.
aMann–Whitney U-test was used for continuous variables and Chi-squared test for categorical variables.
bFisher's exact test.
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and 2 (3.8%) belonged to GOLD stages 1, 2 and 3, respectively.
None of the patients belonged to GOLD stage 4.
A comparison of the patients with ACOS and those with asthma
alone is shown in Table 1. Patients with overlap syndrome were
older and had smoked more than patients with asthma alone.
Overlap patients tended to be more often current smokers and to
have more often signiﬁcant reversibility, but these differences
were not statistically signiﬁcant.
A negative correlation between postbronchodilator FEV1/FVC
and age (Spearman Rho=− 0.28, Po0.001) and pack-years
(Rho=− 0.25, Po0.001) was found (Figure 2).
ROC analysis for age and pack-years revealed that age ⩾ 60
years and smoking for ⩾ 20 pack-years were the best predictors of
ACOS in the study population (Figure 3). The area under the ROC
curve was 0.625 and 0.639 for age and pack-years, respectively.
The cut-off point of 60 years of age yielded 63.5% sensitivity and
59.4% speciﬁcity, and the cut-off point of 20 pack-years 80.8%
sensitivity and 42.8% speciﬁcity, to detect overlap syndrome
(Table 2). However, the combination of both age ⩾ 60 years and
smoking for ⩾ 20 pack-years yielded the best area under the ROC
curve: 0.670, and 53.8% sensitivity and 74.6% speciﬁcity.
The results of the logistic regression analysis are shown in
Table 3. Using the cut-off points given by the ROC analysis, age
and pack-years were the only signiﬁcant factors predicting overlap
syndrome. If the patient was at least 60 years old and had
simultaneously smoked for at least 20 pack-years, the odds ratio
(95% conﬁdence interval) for overlap syndrome was 6.08
(2.11–17.49), P= 0.001, compared with the situation where neither
of these criteria were fulﬁlled. In patients with one criterion
fulﬁlled (age ⩾ 60 or smoking for ⩾ 20 pack-years), the risk of
ACOS was about twice as high as for patients who were younger
than 60 years and had smoked less than 20 pack-years. In
other words, if neither of the criteria (age ⩾ 60 years and
smoking ⩾ 20 pack-years) were fulﬁlled, the prevalence of overlap
syndrome was 11.6% (5/43 patients). If one of the criteria was met,
then overlap syndrome was found in 22.6% (19/84) of the patients.
If both criteria were met the prevalence of overlap syndrome was
found to be 44.4% (28/63 patients).
DISCUSSION
Main ﬁndings
We found the prevalence of asthma–COPD overlap syndrome to
be 27.4% among primary health care asthmatics with no previous
diagnosis of COPD, but who were either current or ex-smokers
with a smoking history of at least 10 pack-years. The patients
with ACOS were older and had smoked more than patients with
asthma alone.
Strengths and limitations of this study
The current study has its weaknesses. First, the number of
participants was relatively small to investigate the differences
between patients with ACOS and asthma alone. However, we
were able to ﬁnd that older age and heavier smoking history
predict ACOS, which are the most common variables found in
other studies too. Moreover, with 190 participants, we were able
to evaluate the prevalence of ACOS among asthmatics with a
positive smoking history, which was the primary objective of the
study. Second, as we did not investigate consecutive patients,
there might have been selection bias. On the other hand, as we
excluded patients with known COPD, and even those using the
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Figure 2. Scatter plots and regression lines showing the association
between age and pack-years versus postbronchodilator FEV1/FVC in
190 asthma patients with a positive smoking history. FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity.
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Figure 3. Receiver operating curve (ROC) analysis of age and
pack-years in 190 asthmatic patients. The cut-off points of 60 years
of age yielded 63.5% sensitivity and 59.4% speciﬁcity and the cut-off
point of 20 pack-years yielded 80.8% sensitivity and 42.8% speciﬁcity
to detect overlap syndrome.
Table 2. The best cut-off values of age and pack-years and their
combination to detect asthma–COPD overlap syndrome among 190
asthmatics with positive smoking history
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Age ⩾ 60 years 63.5 59.4 37.1 81.2
Pack-years ⩾ 20 80.8 42.8 34.7 85.5
Age ⩾ 60 years or pack-years ⩾ 20 90.4 27.5 32.0 88.4
Age ⩾ 60 years and pack-years ⩾ 20 53.8 74.6 44.4 81.1
Abbreviations: COPD, chronic obstructive pulmonary disease; NPV,
negative predictive value; PPV, positive predictive value.
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drugs most commonly prescribed for COPD, one could speculate
that the result might rather be biased the other way. Third, as a
few patients were recruited by private pulmonologists, one could
argue that we did not investigate exclusively primary care
patients. However, in Finland, treatment of the most severe
asthmatics is concentrated in central and university hospitals, and
the recruiting private pulmonologists were emphasised to recruit
only patients who could also be treated by general practitioners.
Moreover, as ACOS patients’ COPD was mostly mild, with 96%
being classed as GOLD stages 1 and 2, we strongly believe that we
investigated primary health care outpatients as was intended.
The study also has its strengths. First, as the criteria for special
reimbursement for asthma medication are strict, we are positive
that all the patients investigated really had asthma. Second, as far
as we know this is the ﬁrst study to investigate the prevalence of
ACOS among primary health care asthmatics with a positive
smoking history but without a previous diagnosis of COPD. In
most earlier studies, the prevalence of ACOS has been evaluated
among COPD patients by asking them if they have doctor-
diagnosed asthma.5,10,15
Interpretation of ﬁndings in relation to previously published work
Hardin et al.5 found the prevalence of asthma–COPD overlap
to be 13% among COPD patients in the COPDGene population.
Miravitlles et al.10 found that 17.4% of COPD patients in the EPI-
SCAN population reported they had previously been diagnosed
with asthma, and thus presented with asthma–COPD overlap.
In the PLATINO study, 22.8% of patients with FEV1/FVC o0.7
reported a prior diagnosis of asthma and can be considered as
overlap patients.15 The 27.4% prevalence of asthma–COPD overlap
syndrome found in our study is slightly higher than in previous
studies. We believe that the major reason for this difference may
be the fact that we investigated a different patient population.
We studied asthmatic patients and investigated how often
their postbronchodilator FEV1/FVC is o0.7, whereas other
studies5,10,15 have investigated how often patients with post-
bronchodilator FEV1/FVC o0.7 report that they have previously
been diagnosed with asthma. On the other hand, prevalences of
overlap even higher than ours have been suggested. For example,
Soriano et al.11 found that as many as 50% of patients with
obstructive pulmonary disease, aged 50 years or more, may suffer
simultaneously from more than one obstructive condition.
The high prevalence of ACOS may be explained by the fact that
asthma and airway hyperresponsiveness are suggested to be risk
factors for developing COPD.2 Lange et al.16 have shown that
decline in pulmonary function is faster in asthmatics than among
those without asthma, and that the decline is fastest among those
asthmatics who smoke. In the study by Vonk et al.,12 16% of
patients with asthma developed irreversible airway obstruction
during a 26-year follow-up. It has been shown that airway
hyperresponsiveness, even without asthma, is an important risk
factor for developing COPD.17
Smoking is the most important risk factor for COPD.2 Therefore,
it is not surprising that the ACOS patients in our study had smoked
more than those with asthma alone. Also in the study by
Lee et al.,18 greater amount of cigarette smoking was related to
the development of ﬁxed airway obstruction among asthmatic
patients.
We found ACOS patients to be older than patients with asthma
alone. In the study by Menezes et al.,6 patients with asthma–COPD
overlap were also older than patients with asthma alone. In that
study, and in the COPDGene study,5 patients with COPD were
older than the overlap patients. These ﬁndings might suggest a
continuum from reversible airway obstruction, via overlap, to
irreversible obstruction in some patients. There is evidence that
some patients with asthma developed irreversible airway obstruc-
tion during long-enough follow-up,12 and that longer duration of
asthma may be associated with irreversible airway obstruction.18
Unfortunately, in the current study, we were unaware of how long
the patients had had asthma. However, we believe that the age of
the patients indirectly reﬂects the duration of asthma, and
therefore, our ﬁnding that age is associated with low FEV1/FVC
is in keeping with the results of the studies suggesting that longer
duration of asthma may be associated with irreversible airway
obstruction. On the other hand, aging per se causes changes in
lung elastic recoil and pulmonary mechanics that causes FEV1/FVC
to decrease; hence, older subjects may be more prone to fulﬁl the
diagnostic criteria of ACOS regardless of the duration of their
asthma.19
Implications for future research, policy and practice
In the current study, the best predictors of ACOS were smoking for
⩾ 20 pack-years and age ⩾ 60 years. If both of these criteria were
met, then ACOS was found in almost half of the patients.
Lee et al.18 found that longer duration of asthma and greater
amount of cigarette smoking were associated with ﬁxed airway
obstruction, that is, ACOS, in patients with severe asthma. In
everyday life, this could mean that in the case of an elderly
asthmatic with a clearly positive smoking history, whose asthma is
difﬁcult to treat, attention should be given not just to the known
asthma, but also one should take the COPD component of
possible ACOS into account as well.
Table 3. Asthma–COPD overlap syndrome in association to
demographic characteristics in 190 asthma patients with positive
smoking history. Results are given by univariable binary logistic
regression analyses
Overlap
syndrome
Unadjusted P value
Na (%) OR 95% CI
Sex
Female 31/112 (27.7) 1.00
Male 21/78 (26.9) 0.96 0.50–1.84 0.91
Smoking
Ex-smoker 23/105 (21.9) 1.00
Current smoker 28/83 (33.7) 1.82 0.95–3.47 0.07
BMI, kg/m2
o25.0 18/56 (32.1) 1.00
25.0–29.9 21/72 (29.2) 0.87 0.41–1.85 0.72
⩾ 30.0 12/60 (20.0) 0.53 0.23–1.23 0.14
Age, years
20–59 19/101 (18.8) 1.00
60–70 33/89 (37.1) 2.54 1.32–4.91 0.005
Pack-years
10–19 10/69 (14.5) 1.00
20–60 42/121 (34.7) 3.14 1.46–6.76 0.004
Age and pack-years
Age o60 and
pack-years o20
5/43 (11.6) 1.00
Age ⩾ 60 or pack-years
⩾ 20
19/84 (22.6) 2.22 0.77–6.43 0.14
Age ⩾ 60 and pack-
years ⩾ 20
28/63 (44.4) 6.08 2.11–17.49 0.001
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmon-
ary disease; OR, odds ratio.
aNumber of patients with overlap syndrome/number of all patients in
the group.
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Conclusions
There is a high prevalence of ACOS among asthmatics with a
positive smoking history but no previous diagnosis of COPD. Age
over 60 years and smoking for more than 20 pack-years were the
best predictors of ACOS in this population.
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